Literature DB >> 18299413

Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.

Theodouli Stergiopoulou1, Joseph Meletiadis, Tin Sein, Paraskevi Papaioannidou, Ioannis Tsiouris, Emmanuel Roilides, Thomas J Walsh.   

Abstract

Patients suffering from invasive mycoses often receive concomitant antifungal therapy and antibacterial agents. Assessment of pharmacodynamic interactions between antifungal and antibacterial agents is complicated by the absence of a common antifungal end point for both agents. Ciprofloxacin has no intrinsic antifungal activity but may interact with antifungal agents, since it inhibits DNA gyrase (topoisomerase II), which is abundant in fungi. We therefore employed isobolographic analysis adapted to incorporate a nonactive agent in order to analyze the potential in vitro interaction between the fluoroquinolone ciprofloxacin and several representative antifungal agents against Candida albicans and Aspergillus fumigatus strains by using a microdilution checkerboard technique. In agreement with earlier in vitro studies, conventional fractional inhibitory concentration index analysis was unable to detect interactions between ciprofloxacin and antifungal agents. However, isobolographic analysis revealed significant pharmacodynamic interactions between antifungal agents and ciprofloxacin against C. albicans and A. fumigatus strains. Amphotericin B demonstrated concentration-dependent interactions for both species, with synergy (interaction indices, 0.14 to 0.81) observed at ciprofloxacin concentrations of <10.64 microg/ml. Synergy (interaction indices, 0.10 to 0.86) was also found for voriconazole and caspofungin against A. fumigatus. Isobolographic analysis may help to elucidate the pharmacodynamic interactions between antifungal and non-antifungal agents and to develop better management strategies against invasive candidiasis and aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18299413      PMCID: PMC2415767          DOI: 10.1128/AAC.00735-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.

Authors:  Joseph Meletiadis; Debbie T A te Dorsthorst; Paul E Verweij
Journal:  Int J Antimicrob Agents       Date:  2006-10-19       Impact factor: 5.283

2.  Gabapentin synergistically interacts with topiramate in the mouse maximal electroshock seizure model: an isobolographic analysis.

Authors:  Jarogniew J Luszczki; Stanisław J Czuczwar
Journal:  Pharmacol Rep       Date:  2006 Nov-Dec       Impact factor: 3.024

3.  Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.

Authors:  Nathan P Wiederhold; Vincent H Tam; Jingduan Chi; Randall A Prince; Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

4.  Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans.

Authors:  E Sasaki; S Maesaki; Y Miyazaki; K Yanagihara; K Tomono; T Tashiro; S Kohno
Journal:  J Infect Chemother       Date:  2000-09       Impact factor: 2.211

5.  Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion.

Authors:  A Nosari; P Oreste; R Cairoli; M Montillo; G Carrafiello; A Astolfi; G Muti; L Marbello; A Tedeschi; E Magliano; E Morra
Journal:  Am J Hematol       Date:  2001-12       Impact factor: 10.047

6.  Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.

Authors:  Joseph Meletiadis; Vidmantas Petraitis; Ruta Petraitiene; Pengxin Lin; Theodouli Stergiopoulou; Amy M Kelaher; Tin Sein; Robert L Schaufele; John Bacher; Thomas J Walsh
Journal:  J Infect Dis       Date:  2006-08-28       Impact factor: 5.226

Review 7.  Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century.

Authors:  T J Walsh; A H Groll
Journal:  Transpl Infect Dis       Date:  1999-12       Impact factor: 2.228

8.  Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.

Authors:  Joseph Meletiadis; Theodouli Stergiopoulou; Elizabeth M O'Shaughnessy; Joanne Peter; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

9.  Vasodilator effects of sodium nitroprusside, levcromakalim and their combination in isolated rat aorta.

Authors:  F Pérez-Vizcaíno; A L Cogolludo; F Zaragozá-Arnáez; S Fajardo; M Ibarra; J G López-López; J Tamargo
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 10.  Fever of unknown origin in febrile leukopenia.

Authors:  Anastasia Antoniadou; Helen Giamarellou
Journal:  Infect Dis Clin North Am       Date:  2007-12       Impact factor: 5.982

View more
  7 in total

Review 1.  Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.

Authors:  Sharon C-A Chen; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Virulence       Date:  2011-07-01       Impact factor: 5.882

2.  Synergistic interaction of the triple combination of amphotericin B, ciprofloxacin, and polymorphonuclear neutrophils against Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Thomas J Walsh; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

3.  Fungal keratitis responsive to moxifloxacin monotherapy.

Authors:  Alice Y Matoba
Journal:  Cornea       Date:  2012-10       Impact factor: 2.651

4.  Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Ioannis Tsiouris; Emmanuel Roilides; Thomas J Walsh
Journal:  J Antimicrob Chemother       Date:  2008-12-24       Impact factor: 5.790

Review 5.  A review of cosmetic contact lens infections.

Authors:  Chris H L Lim; Fiona Stapleton; Jodhbir S Mehta
Journal:  Eye (Lond)       Date:  2018-11-01       Impact factor: 3.775

Review 6.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

7.  Metrics of Antifungal Effects of Ciprofloxacin on Aspergillus fumigatus Planktonic Growth and Biofilm Metabolism; Effects of Iron and Siderophores.

Authors:  Gabriele Sass; Lynn Scherpe; Marife Martinez; Julianne J Marsh; David A Stevens
Journal:  J Fungi (Basel)       Date:  2022-02-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.